Log in

NASDAQ:GWPHGW Pharmaceuticals PLC- Stock Price, Forecast & News

$127.90
-0.21 (-0.16 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$127.79
Now: $127.90
$130.12
50-Day Range
$120.20
MA: $125.88
$131.87
52-Week Range
$67.98
Now: $127.90
$175.35
Volume200,400 shs
Average Volume282,066 shs
Market Capitalization$3.97 billion
P/E Ratio130.51
Dividend YieldN/A
Beta1.94
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More
GW Pharmaceuticals PLC- logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$311.33 million
Cash Flow$0.01 per share
Book Value$23.48 per share

Profitability

Net Income$-9,020,000.00

Miscellaneous

Employees791
Market Cap$3.97 billion
Next Earnings DateN/A
OptionableOptionable

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

How has GW Pharmaceuticals PLC-'s stock been impacted by COVID-19 (Coronavirus)?

GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GWPH stock has increased by 47.2% and is now trading at $127.90. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GW Pharmaceuticals PLC-?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GW Pharmaceuticals PLC-.

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) announced its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.88) by $0.64. The biopharmaceutical company earned $120.60 million during the quarter, compared to the consensus estimate of $84.93 million. GW Pharmaceuticals PLC- had a negative return on equity of 9.87% and a net margin of 8.42%. The firm's quarterly revenue was up 207.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.14) earnings per share. View GW Pharmaceuticals PLC-'s earnings history.

What price target have analysts set for GWPH?

11 equities research analysts have issued 1 year price objectives for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $128.00 to $275.00. On average, they anticipate GW Pharmaceuticals PLC-'s share price to reach $187.73 in the next twelve months. This suggests a possible upside of 46.8% from the stock's current price. View analysts' price targets for GW Pharmaceuticals PLC-.

Has GW Pharmaceuticals PLC- been receiving favorable news coverage?

Media coverage about GWPH stock has been trending very negative this week, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. GW Pharmaceuticals PLC- earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about GW Pharmaceuticals PLC-.

Who are some of GW Pharmaceuticals PLC-'s key competitors?

What other stocks do shareholders of GW Pharmaceuticals PLC- own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA), Walt Disney (DIS), Aurora Cannabis (ACB), Intel (INTC) and Gilead Sciences (GILD).

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the following people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 48)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)
  • Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61)

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

Who are GW Pharmaceuticals PLC-'s major shareholders?

GW Pharmaceuticals PLC-'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include Investors Financial Group LLC (0.03%), Envestnet Asset Management Inc. (0.01%) and Modus Advisors LLC (0.00%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View institutional ownership trends for GW Pharmaceuticals PLC-.

Which major investors are buying GW Pharmaceuticals PLC- stock?

GWPH stock was bought by a variety of institutional investors in the last quarter, including Investors Financial Group LLC, Modus Advisors LLC, and Envestnet Asset Management Inc.. View insider buying and selling activity for GW Pharmaceuticals PLC-.

How do I buy shares of GW Pharmaceuticals PLC-?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GWPH stock can currently be purchased for approximately $127.90.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $3.97 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.

What is GW Pharmaceuticals PLC-'s official website?

The official website for GW Pharmaceuticals PLC- is www.gwpharm.com.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.